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The gut microbiota has been implicated in obesity
and cardiometabolic diseases, although evidence
in humans is scarce. We investigated how gut
microbiota manipulation by antibiotics (7-day
administration of amoxicillin, vancomycin, or pla-
cebo) affects host metabolism in 57 obese, pre-
diabetic men. Vancomycin, but not amoxicillin,
decreased bacterial diversity and reduced Firmi-
cutes involved in short-chain fatty acid and bile
acid metabolism, concomitant with altered plasma
and/or fecal metabolite concentrations. Adipose
tissue gene expression of oxidative pathways
was upregulated by antibiotics, whereas immune-
related pathways were downregulated by vanco-
mycin. Antibiotics did not affect tissue-specific
insulin sensitivity, energy/substrate metabolism,
postprandial hormones and metabolites, systemic
inflammation, gut permeability, and adipocyte
size. Importantly, energy harvest, adipocyte size,
and whole-body insulin sensitivity were not altered
at 8-week follow-up, despite a still considerably
altered microbial composition, indicating that inter-
ference with adult microbiota by 7-day antibiotic
treatment has no clinically relevant impact on meta-
bolic health in obese humans.INTRODUCTION
Accumulating evidence indicates that the composition of the gut
microbiota plays a prominent role in body weight regulation and
the development of type 2 diabetes mellitus (Greenhill, 2015;
Khan et al., 2014). The gut microbiota regulates energy extrac-
tion from otherwise indigestible carbohydrates, determines the
integrity of the intestinal epithelial layer, and influences the pro-
duction and absorption of multiple signaling molecules involved
in host metabolism. Several studies have demonstrated that
germ-free mice are protected from diet-induced obesity, low-
grade inflammation, and glucose intolerance as compared to
conventionally raised animals (Ba¨ckhed et al., 2004; Turnbaugh
et al., 2006). Furthermore, it has been shown that transferring mi-
crobiota via fecal transplantation evoked alterations in body
weight and insulin sensitivity in both rodents (Ba¨ckhed et al.,
2004) and humans (Hartstra et al., 2015; Vrieze et al., 2013)
Taken together, these data indicate that modulation of the gut
microbiota may provide a promising avenue to target obesity-
related metabolic disorders (Cox and Blaser, 2013).
The gut microbiota composition can be modulated by, among
others, prebiotics, probiotics, and antibiotics (Marchesi et al.,
2015), thereby altering the presence and expression of microbial
genes and derived metabolites such as bile acids (BAs) and
short-chain fatty acids (SCFAs) (Canfora et al., 2015; Jones
et al., 2014). Particularly, the use of antibiotics has been associ-
ated with increased metabolic impairments, mainly when expo-
sure occurs in early life (Cox and Blaser, 2015; Jess, 2014). Of
note, these findings are primarily based on animal studies, inCell Metabolism 24, 63–74, July 12, 2016 ª 2016 Elsevier Inc. 63







Age (years) 60.9 ± 1.7 55.7 ± 1.5 60.6 ± 1.5
Body weight (kg) 96.7 ± 2.3 96.3 ± 2.5 97.6 ± 1.9
Body mass index (kg/m2) 31.0 ± 0.5 31.1 ± 0.8 31.5 ± 0.6
Waist/hip ratio 1.04 ± 0.01 1.04 ± 0.01 1.07 ± 0.01
Waist circumference (cm) 98.0 ± 8.1 101.1 ± 6.4 106.7 ± 6.3
Fasting glucose (mM) 6.0 ± 0.1 6.1 ± 0.1 6.1 ± 0.1
2 hr OGTT glucose (mM) 7.7 ± 0.4 7.0 ± 0.5 7.2 ± 0.4
Fasting insulin (mU/l) 15.7 ± 1.5 17.9 ± 1.6 16.8 ± 1.1
HOMA-IR 4.2 ± 0.4 4.9 ± 0.5 4.6 ± 0.3
HbA1c (%) 5.5 ± 0.1 5.6 ± 0.1 5.6 ± 0.1
Data are mean ± SEM (n = 56). Homeostasis model assessment of insulin
resistance (HOMA-IR), 75 g oral glucose tolerance test (OGTT), glycated
haemoglobin (HbA1c).which the animals have mostly been exposed to a combination
of antibiotics for periods varying from 2 to 20 weeks (Cani
et al., 2008; Chou et al., 2008; Hwang et al., 2015; Membrez
et al., 2008; Murphy et al., 2013). It has recently been shown
that antibiotics may improve peripheral insulin sensitivity in a
small number of obese subjects (Vrieze et al., 2014). Neverthe-
less, the effects observed in the latter study were relatively
minor, and importantly, the study was not placebo-controlled.
Thus, well-controlled, large human studies examining the effects
and underlying mechanisms of microbiota modulation on host
metabolism are currently lacking.
Here, we report on a randomized, double-blind, placebo-
controlled trial that was designed to investigate the effects of
broad- and narrow-spectrum antibiotic treatment for 7 days on
gut microbiota composition, tissue-specific insulin sensitivity,
energy expenditure, substrate oxidation, fecal and plasma BA
and SCFA concentrations, gut permeability, abdominal subcu-
taneous adipocyte size, and systemic low-grade inflammation
in obese men with impaired glucose homeostasis. Moreover,
8 weeks after cessation of antibiotic treatment, we again deter-
mined microbiota composition, whole-body insulin sensitivity
(HOMA-IR), fecal energy harvest, and adipocyte size.
RESULTS AND DISCUSSION
Subject Characteristics
To study the role of the gut microbiota, we randomized 57
overweight and obese 35–70 year old Caucasian men to oral
administration of the broad-spectrum antibiotic amoxicillin
(AMOX), narrow-spectrum antibiotic vancomycin (VANCO,
directed against Gram-positive bacteria), or placebo (PLA) for
7 days. No significant differences in baseline characteristics
were present between groups (Table 1). All subjects had
impaired fasting glucose levels (plasma glucose R 5.6 mmol/l)
and/or impaired glucose tolerance (2 hr plasma glucose during
a 75 g oral glucose tolerance test 7.8–11.1 mmol/l) and were
insulin resistant (homeostasis model assessment for insulin
resistance; HOMA-IR > 2.2). One subject randomized to the
AMOX intervention was considered a dropout due to use of other64 Cell Metabolism 24, 63–74, July 12, 2016antibiotics during the study period. No serious adverse events
and only a few cases of mild gastrointestinal discomfort were re-
ported. There were no differences in daily energy and macronu-
trient intake, as monitored by a 3-day food diary, between and
within groups before and after intervention. Furthermore, body
weight remained unchanged for all treatment groups throughout
the study period and at follow-up (data not shown).
Efficacy of Microbiota Manipulation by Antibiotic
Treatment
The fecal microbiota composition was determined by analyzing
16S rRNA gene amplicons, using the Human Intestinal Tract
Chip Microarray (HITchip) (Rajilic-Stojanovic et al., 2009), which
showed that 7-day VANCO markedly decreased microbial
diversity (p < 0.001), whereas this was not affected by AMOX
(p = 0.42) as compared to PLA (Figure 1). VANCO decreased
the relative abundance of mainly Gram-positive bacteria of the
Firmicutes phylum. Among the most strongly affected groups
were genus-like groups that contain known butyrate-producing
species from Clostridium clusters IV and XIVa, such as Copro-
coccus eutactus, Faecalibacterium prausnitzii, and Anaerostipes
caccae, as well as species involved in BA dehydroxylation such
asClostridium leptum. Conversely, Gram-negative Proteobacte-
ria, members of Clostridium cluster IX and VANCO-resistant
Gram-positive Bacilli such as Lactobacillus plantarum and
Enterococcus, showed increased relative abundance after
VANCO treatment (Figure 1; Table S1), which is in line with pre-
vious studies (Vrieze et al., 2014; Yap et al., 2008). This pattern
was confirmed with a supervised machine-learning technique
(Random Forests analysis, Table S2). Importantly, microbiota
composition was still affected 8 weeks after cessation of VANCO
treatment. Microbial diversity was still lower (q = 0.053), and
overall similarity and composition were deviant from baseline
(pre-treatment) as compared to PLA. Although the bacterial
groups that increased in abundance due to VANCO treatment
had in general returned to baseline levels, several members
of Clostridium clusters IV and XIVa were still decreased
as compared to PLA. Furthermore, observed dynamics with
respect to gut microbiota composition and diversity were
individual specific (Figure S1). In contrast, AMOX treatment did
not affect microbiota composition after 7 days treatment or at
8 weeks follow-up compared to PLA, which is in accordance
with a previous study in obese humans (Vrieze et al., 2014).
Antibiotic Treatment Does Not Affect Tissue-Specific
Insulin Sensitivity
The primary outcome of this study was peripheral insulin sensi-
tivity (insulin-stimulated glucose rate of disappearance, Rd), as
determined by a two-step hyperinsulinemic-euglycemic clamp
with [6,6-2H2]-glucose tracer infusion. Antibiotic treatment did
not significantly alter Rd as compared to PLA (Figure 2). Addi-
tionally, no effects were found on hepatic and adipose tissue
(AT) insulin sensitivity, as determined by the insulin-mediated
suppression of endogenous glucose production (EGP) and
plasma free fatty acid (FFA) concentrations, respectively. In
accordance, antibiotic treatment neither altered whole-body
insulin sensitivity (HOMA-IR) immediately after cessation of
treatment nor at 8 weeks follow-up (Figure S2). Our data are
in contrast with several previous studies in rodents, which
Figure 1. The Effect of Vancomycin and Amoxicillin Treatment on Microbiota Composition
Heatmap of bacterial groups (at genus and order like level with Gram staining between brackets) whose relative abundance was significantly different (q < 0.05)
post-treatment within the VANCO group. Color value shows log10 fold changes compared to baseline. Genus like groups containing known butyrate producing
and BA dehydroxylating species are depicted in green and red, respectively. * Groups that exhibited a significant difference between VANCO and PLA
treatments. See also Figure S1 and Tables S1 and S2.indicated that antibiotic treatment may improve glucose homeo-
stasis and metabolic impairments (Bech-Nielsen et al., 2012;
Carvalho et al., 2012; Chou et al., 2008; Hwang et al., 2015;
Membrez et al., 2008; Murphy et al., 2013; Rune et al., 2013).
Nevertheless, a more recent study showed that VANCO-treated
mice had little weight change and no improvement in glycemic
control (Rajpal et al., 2015). Consistent with the present data, a
4-day treatment with a broad-spectrum antibiotic cocktail did
not affect postprandial glucose metabolism in lean, healthy
men (Mikkelsen et al., 2015a). Furthermore, it has recently
been shown in a limited number of obese subjects with themeta-
bolic syndrome that VANCO slightly but significantly reducedperipheral insulin sensitivity, despite comparable changes in mi-
crobial composition and BA metabolism as found in the present
study (Vrieze et al., 2014). Although the data of the latter study
seems at odds with the present findings, it is important to
emphasize that in the study by Vrieze and colleagues (Vrieze
et al., 2014) the modest (4%) VANCO-induced decrease in pe-
ripheral insulin sensitivity was based on a within-group compar-
ison (post-treatment versus pre-treatment), since a placebo
group was not included in the study design. Additionally, in the
present study, follow-up measurements that were performed
8 weeks after treatment cessation also did not show an effect
on whole-body insulin sensitivity, despite a still considerablyCell Metabolism 24, 63–74, July 12, 2016 65
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Figure 2. The Effect of 7 Days Placebo, Amoxicillin, and Vancomycin on Hepatic, Adipose Tissue, and Peripheral Insulin Sensitivity
Data are mean ± SEM (n = 56).
(A) (Fasting) liver endogenous glucose production (EGP).
(B) Steady-state insulin-mediated EGP suppression (%) upon 10 mU/m2/min insulin infusion.
(C) Steady-state 10 mU/m2/min insulin-mediated suppression (%) of circulating FFAs as measure for adipose tissue insulin sensitivity.
(D) 40 mU/m2/min insulin-stimulated glucose disposal (Rd). See also Figures S2, S5, S6 and Table S4.altered microbial composition as compared to pre-treatment as
well as placebo.
Antibiotic Treatment Does Not Affect Energy and
Substrate Metabolism
To examine the effect of gut microbiota modulation on post-
prandial metabolite concentrations, energy expenditure, and
substrate oxidation, we performed a high-fat mixed-meal test
(2.6MJ [61E% fat, 33E% carbohydrates, 6E% protein]). We
determined arterialized plasma metabolite concentrations and
measured energy expenditure and substrate oxidation by
whole-body indirect calorimetry. Neither VANCO nor AMOX
significantly affected basal and postprandial plasma glucose,
insulin, FFA, triacylglycerol (TAG), and lactate concentrations
(Table 2; Figure S3; Table S3). Also, no significant effects on
basal and postprandial energy expenditure, carbohydrate, and
fat oxidation were found (Figure 3). After adjustment for fecal
weight, intestinal energy harvest, which is reflected by daily fecal
energy content, was neither changed immediately after treat-
ment cessation, nor after 8 weeks follow-up (Figure 3). Although
previous studies in rodents have shown a prominent role of the
gut microbiota in energy harvest and body weight (Cani et al.,
2008; Turnbaugh et al., 2006), our findings suggest that
antibiotics do not alter energy harvest in humans. Of note, in
rodent studies, animals were exposed to antibiotics in their
drinking water for 2 up to 20 weeks (Bech-Nielsen et al., 2012;66 Cell Metabolism 24, 63–74, July 12, 2016Cani et al., 2008; Carvalho et al., 2012; Chou et al., 2008; Hwang
et al., 2015; Membrez et al., 2008; Murphy et al., 2013; Rune
et al., 2013). Similarly, more prolonged treatment (4 to 6 weeks)
with a higher dosage or a combination of different antibiotics
increased body weight in endocarditis patients (Million et al.,
2013; Thuny et al., 2010). These studies may indicate that a
long-term dysbalance in microbiota composition has more
pronounced effects as compared to short-term manipulation.
However, it is hard to differentiate between the role of the gut
microbiota and systemic effects of antibiotics in the latter
studies. Noteworthy, we have applied a 2-day wash-out period
before post-treatment measurements were performed to
exclude that effects may be mediated via direct systemic effects
of antibiotics. Additionally, VANCO does not pass the gastroin-
testinal barrier and, therefore, does not reach the circulation
(Gonzales et al., 2010).
Antibiotic Treatment Does Not Alter Gut Permeability
and Systemic Inflammatory Markers
We investigated the effect of 7 days of AMOX and VANCO
treatment on gut permeability and the related translocation of
bacterial lipopolysaccharide (LPS) from the intestinal lumen
into the circulation. The pronounced VANCO-induced microbial
alterations were not accompanied by changes in small intestine
and proximal colon permeability (Figure S4), as assessed
by a multi-saccharide test (van Wijck et al., 2013). This is in
Table 2. Effect of 7 Days Placebo, Amoxicillin, and Vancomycin on Metabolic, Inflammatory, and Hormonal Parameters
Fasting Plasma Metabolite, Hormone and ANGPTL4 Concentrations
Variable PLA (N = 14) AMOX (N = 12) VANCO (N = 12) p valuea
Glucose (mM) Pre 6.31 ± 1.12 6.48 ± 0.25 6.25 ± 0.19 0.177b
Post 6.29 ± 0.14 6.39 ± 0.20 5.99 ± 0.13
TAG (mM) Pre 1,404 ± 166 1,085 ± 151 1,027 ± 88 0.511
Post 1,470 ± 215 1,034 ± 149 1,058 ± 101
FFA (mM) Pre 699 ± 34 683 ± 48 679 ± 38 0.423b
Post 661 ± 34 579 ± 58 626 ± 54
Lactate (mM) Pre 0.80 ± 0.07 0.93 ± 0.04 0.88 ± 0.11 0.238
Post 0.91 ± 0.11 0.90 ± 0.05 0.79 ± 0.06
Insulin (mU/l) Pre 11.5 ± 1.3 12.6 ± 1.3 14.3 ± 1.8 0.504
Post 12.7 ± 1.6 13.4 ± 1.8 13.9 ± 1.5
GLP-1 (pmol/l) Pre 8.7 ± 0.7 8.5 ± 0.7 9.7 ± 1.1 0.670
Post 9.3 ± 1.1 8.7 ± 0.8 10.2 ± 1.2
Leptin (ng/ml) Pre 11.4 ± 1.6 10.1 ± 2.1 9.7 ± 0.8 0.106b
Post 12.9 ± 2.3 10.0 ± 1.8 8.8 ± 0.8
ANGPTL4 (ng/ml) Pre 5.1 ± 0.7 4.3 ± 0.5 4.9 ± 0.5 0.137
Post 5.5 ± 0.7 3.8 ± 0.5 4.3 ± 0.3
Fasting inflammatory marker concentrations
PLA (N = 19) AMOX (N = 18) VANCO (N = 19) p valuea
LBP (pg/ml) Pre 19.6 ± 1.8 17.5 ± 1.8 25.7 ± 4.3 0.456
Post 18.4 ± 3.3 20.4 ± 2.9 23.6 ± 3.6
IL-6 (pg/ml) Pre 0.8 ± 0.1 0.8 ± 0.1 1.0 ± 0.1 0.775
Post 1.0 ± 0.1 0.8 ± 0.1 1.1 ± 0.1
IL-8 (pg/ml) Pre 6.2 ± 0.5 4.3 ± 0.4c 5.2 ± 0.4 0.444
Post 5.9 ± 0.5 4.8 ± 0.4 5.9 ± 0.4
TNF-a (pg/ml) Pre 2.6 ± 0.1 2.3 ± 0.1c 2.7 ± 0.1 0.424
Post 2.7 ± 0.1 2.5 ± 0.1 2.8 ± 0.1
Data are mean ± SEM. For determination of plasma hormones and metabolites, only a subgroup of n = 38 was analyzed. There were no significant
differences between the groups after intervention (Post) compared to baseline (Pre). Triacylglycerol (TAG), free fatty acids (FFA), glucagon-like peptide
(GLP), angiopoietin-like 4 (ANGPTL4), lipopolysaccharide-binding protein (LBP), interleukin (IL), tumor necrosis factor (TNF).
ap value represents the overall intervention effect between groups assessed by repeated-measures ANOVA (time 3 treat p value) or ANCOVA when
baseline concentrations were different between groups.
bTime effect (p < 0.05).
cBaseline group difference (p < 0.05). See also Figures S3 and S4 and Table S3.accordance with unchanged LPS-binding protein (LBP) concen-
trations after VANCO and AMOX treatment as compared to PLA
(Table 2). LPS, which is released by Gram-negative bacteria,
may trigger the immune system by increasing inflammatory
cytokine production in AT and is frequently used as an indicator
of metabolic endotoxemia (Cani et al., 2007). Therefore, we
have additionally determined plasma interleukin (IL)-6, IL-8,
and tumor necrosis factor (TNF)-a concentrations. In line with
unchanged LBP concentrations, neither of these inflammatory
factors was affected by 7-day VANCO or AMOX as compared
to PLA. This was observed despite a substantial increase in rela-
tive abundance of potentially pro-inflammatory Gram-negative
Proteobacteria.
Vancomycin Inhibits BA Conversion and SCFA
Production
SCFAs, notably butyrate, can be produced by several groups
within the Firmicutes phylum (mainly Clostridium clusters XIVaand IV, including Coprococcus eutactus and F. prausnitzii),
some of which are also involved in BA dehydroxylation (Jones
et al., 2014; Ridlon et al., 2006). Indeed, we found a decreased
relative abundance of these groups after VANCO, which was
accompanied by a marked reduction in plasma (p = 0.005) and
fecal (p = 0.001) concentrations of secondary BAs as compared
to PLA (Figure 4). This was accompanied by an increase of fecal
primary BAs (p = 0.013). In addition, fecal SCFA concentrations
(acetate (p = 0.001), butyrate (p < 0.001), caproate (p < 0.001),
and valerate (p = 0.009)) were significantly decreased following
VANCO, while in plasma only butyrate tended to decrease after
VANCO (p = 0.078) but not following AMOX treatment (Figure 5).
Although BAs and SCFAs may control incretin release (Brigh-
ton et al., 2015; Canfora et al., 2015) and affect energy meta-
bolism in rodents (Gao et al., 2009), no effects on postprandial
energy and substrate metabolism and fasting and postprandial
glucagon-like peptide 1 (GLP-1) concentrations were found in




Figure 3. The Effect of 7 Days Placebo, Amoxicillin, and Vancomycin on energy Expenditure, Substrate Metabolism, and Fecal Energy
Excretion
Data are mean ± SEM. Indirect calorimetry was performed during fasting conditions and for 4 hr after intake of a liquid high-fat mixedmeal (HFMM) in a subgroup
of n = 37. Mean O2 consumption and CO2-production over 20 min were used for calculations.
(A–D) Fasting respiratory quotient (RQ), energy expenditure (EE), carbohydrate oxidation, and fat oxidation did not differ after intervention (time 3 treat
p value > 0.05). Incremental AUCs after ingestion of HFMM were also not affected by AMOX or VANCO.
(E) Fecal energy excretion (kcal/day) did not significantly change after VANCO or AMOX compared to PLA (n = 56).Antibiotic Treatment Alters Adipose Tissue Gene
Expression but Not Adipocyte Morphology
To determine the effect of an altered gut microbiota composition
on AT, we collected abdominal subcutaneous AT biopsies to
examine adipocyte size and gene expression profiles using Affy-
metrix microarray transcriptomic analysis. Antibiotic treatment
had no significant effect on abdominal subcutaneous adipocyte
size and the proportion of small and large adipocytes, neither
directly after treatment cessation nor at 8 weeks follow-up (Fig-68 Cell Metabolism 24, 63–74, July 12, 2016ure S5). Remarkably, when comparing the gene expression data
with the Kyoto Encyclopedia of Genes andGenomes (KEGG), we
found that VANCO and, to a lesser extent, AMOX increased AT
expression of genes involved in pathways related to peroxi-
some-proliferator activated receptor (PPAR)-signaling and of
genes encoding proteins involved in the mitochondrial Krebs cy-
cle, fatty acid degradation, and other components of the oxida-
tive machinery, suggestive of increased oxidative metabolism in
AT (Figure S6). In addition, VANCO decreased the expression of















































































































Figure 4. The Effect of 7 Days Placebo, Amoxicillin, and Vancomycin on BA Concentrations in Plasma and Feces
Data are mean ± SEM. In a subgroup of n = 37.
(A) Plasma postprandial primary BA did not change significantly.
(B–D) VANCO increased fecal primary BA (B), decreased plasma secondary BA (C), and fecal secondary BA (D) compared to PLA and AMOX. * time 3 treat
p value < 0.05 for VANCO versus PLA.histone clustering genes. Although we found no differences in
adipocyte morphology and circulating FFA, TAG, leptin, and an-
giopoietin-like 4 (ANGPTL4) concentrations (Table 2), these al-
terations in the AT transcriptome may translate into changes in
AT function over longer periods of time.
Finally, VANCO decreased the expression of gene sets
involved in apoptosis and nuclear factor NFkB signaling as well
as adaptive and innate immune responses, including genes
of major histocompatibility complex-I, T cell, B cell, and natural
killer cell signaling. In contrast, genes related to lysosomal
breakdown were upregulated as compared to PLA (Table S4).
Lower NFkB-dependent gene expression and diminished NK
and CD8+ T cell function in macrophages have been observed
in germ-free and antibiotic-treated mice (Ganal et al., 2012). In
the latter study, the effects were ascribed to a reduced activation
of Farnesoid X receptors by a reduction of unconjugated and
secondary BAs (Jones et al., 2014), which seems in line with
the present findings. In addition, although the exact role of
SCFAs in the systemic and AT immune cell responses is un-
known, SCFAs may be involved in the regulation of T cells in
the gut and peripheral tissues via the G protein-coupled receptor
43 (Brestoff and Artis, 2013; Canfora et al., 2015; Fukuda et al.,2011; Furusawa et al., 2013). Despite the effects of antibiotic
treatment on the KEGG pathways described above, no signifi-
cant associations (FDR < 0.25) were found between individual
bacterial groups and AT gene expression (data not shown).
Microbial Groups Are Not Associated with Host
Metabolic Parameters
Although overall host metabolism did not change significantly
following antibiotic treatment, we used univariate and multivar-
iate statistics (redundancy analysis) to assess possible associa-
tions between specific characteristics of gut microbial profiles
and host metabolic parameters. However, we did not find any
significant and consistent associations when we evaluated the
abundance and dynamics of individual bacterial taxa, combina-
tions of taxa, the complete microbiota, and bacterial diversity at
baseline, as well as 7 days and 8 weeks post-intervention.
Furthermore, we investigated whether we could identify and
connect patterns of specific metabolic and/or microbiological
perturbations with the response to the intervention. First, we
evaluated the stratification of subjects based on the extent of
the microbial shift in diversity, as well as microbial composition.





























































































































Figure 5. The Effect of 7 Days Placebo, Amoxicillin, and Vancomycin on Plasma and Fecal SCFA Concentrations
(A and C–E) Data are mean ± SEM (n = 56). No significant effect was found for (A) plasma acetate, (C) plasma propionate, (D) fecal propionate, and a trend
(#p = 0.07) for (E) plasma butyrate.
(B and F) Fecal acetate and butyrate decreased after VANCO treatment but not after AMOX. * time 3 treat p value < 0.05 for VANCO versus PLA and versus
AMOX.response to the intervention, we used univariate and cluster
analysis to discover microbial patterns. Lastly, we used latent
class analysis (McCutcheon, 1987) to define groups of subjects
with certain metabolic patterns before and after treatment.
Neither of these analyses showed groups of individuals with spe-
cific associations of the microbiota with host metabolic parame-
ters (data not shown).
PERSPECTIVES
In the present study, we demonstrated that seven days VANCO
treatment markedly affected microbial diversity and composi-70 Cell Metabolism 24, 63–74, July 12, 2016tion, which was accompanied by a reduced conversion of pri-
mary to secondary BAs and a lower production of SCFAs in
the gut. Importantly, these alterations did not translate into sig-
nificant effects on peripheral, hepatic and AT insulin sensitivity,
energy and substrate metabolism, and systemic low-grade
inflammation immediately after treatment cessation. Moreover,
no clinically relevant effects on energy harvest, abdominal sub-
cutaneous adipocyte size, and whole-body insulin sensitivity
(HOMA-IR) were found at 8 weeks follow-up. In contrast to
VANCO, no effects of AMOX treatment on gut microbial compo-
sition, and metabolic and inflammatory parameters were found.
Taken together, the present study implies that interferencewith a
resilient adult microbiota by antibiotics has no clinically relevant
short-term (7 days) and long-term (8 weeks) effects on the meta-
bolic parameters measured in this study. This contradicts many
previous rodents studies and again highlights that rodent data
cannot always be extrapolated to humans.
Noteworthy, several nuances have to be made with respect to
the conclusions of the present study. First, since we studied
obese, insulin-resistant men with impaired glucose metabolism,
we cannot exclude that microbiota manipulation by antibiotics
may have more pronounced effects in women or less metaboli-
cally compromised individuals. Second, the duration of the
intervention was relatively short, compared to rodent studies.
Furthermore, it has been demonstrated that the risk of devel-
oping type 2 diabetes was increased when subjects were
exposed to >5 antibiotic treatments (Mikkelsen et al., 2015b)
and that the number of prescriptions may accelerate the ag-
ing-related decline of intestinal integrity (Kerr et al., 2015). Of
note, the participants that were included in the present study
had received on average 1.7 antibiotic treatments over the
past 10 years, without any antibiotic use 3 months prior to the
start of the study. As mentioned above, several studies have
indicated that a long-term or more frequent perturbation in
microbiota composition may have more pronounced effects on
metabolic health than short-term manipulation. For this reason,
it is important to emphasize that the present study does not
exclude an important role for the gut microbiota manipulations
in changes of host metabolism. This should be further investi-
gated in future prospective and long-term (dietary, prebiotic,
and/or probiotic) intervention studies in humans.
EXPERIMENTAL PROCEDURES
Study Participants
57 low-active (<3 hr organized sports activities per week), weight-stable (<2 kg
body weight change 3 months prior to inclusion) overweight/obese (BMI
25–35 kg/m2) Caucasian men, between 35 and 70 years with impaired glucose
metabolism (either fasting glucose >5.6 mmol/l, and/or 2 hr glucose between
7.8–11 mmol/l) and HOMA-IR > 2.2 were included in this study (https://
ClinicalTrials.gov, NCT02241421). Subjects were recruited via advertisements
in local newspapers and were all living in the area around Maastricht, The
Netherlands. All subjects gave written informed consent for participation in
this study, which was reviewed and approved by the local Medical Ethical
Committee of Maastricht University Medical Center+. All procedures were
according to the declaration of Helsinki (revised version, October 2008). Exclu-
sion criteria were the use of antibiotics for a period of 3 months before entering
the study, known allergic reactions to any type of antibiotics; hearing disor-
ders; cancer; liver malfunction; major illnesses with a life expectancy less
than 5 years and pulmonary; hepatic, cardiovascular, kidney, and gastrointes-
tinal disease. Subjects did not use b-blockers, lipid- and glucose-lowering
drugs, anti-oxidants, or chronic corticosteroids.
Study Design and Randomization
This randomized, placebo-controlled, double-blind study had a three-armed
parallel design. Participants were randomized to oral intake of amoxicillin
(broad-spectrum antibiotic), vancomycin (directed against Gram-positive bac-
teria), or placebo (microcrystalline cellulose) for 7 consecutive days (1,500mg/
day). Antibiotics and placebo were equally capsulated to blind the content to
subjects and investigators (BasicPharma, The Netherlands). The allocation
sequence was established by computer-generated randomization (https://nl.
tenalea.net). Block-randomization with stratification for BMI, age, and 2 hr-
glucose values was used to increase the homogeneity of the treatment arms
(block size, n = 6). After completion of the study, returned capsules were
counted to assess compliance. Participants were asked to maintain theirhabitual physical activity pattern and dietary habits (monitored by 3-day
food diaries) throughout the study. The evening before an investigation
day, a low-fiber, low-fat meal was consumed. Before and after intervention,
study measurements were conducted following a 10-hr overnight fast.
To ensure complete systemic and gastrointestinal clearance of antibiotics, a
2-day wash-out period was taken into account before post-treatment mea-
surements. Participants returned for a follow-up visit 8 weeks after treatment
cessation.
Hyperinsulinemic-Euglycemic Clamp
A two-step hyperinsulinemic–euglycemic clamp combined with a [6,6-2H2]-
glucose tracer (Cambridge Isotope Laboratorieswas performed to measure
Rd, EGP (Hulzebos et al., 2001) and the insulin-mediated suppression of
FFAs (DeFronzo et al., 1979; Steele, 1959). Blood samples were taken from
a superficial dorsal hand vein, which was arterialized by using a hot-box
(50C). After a bolus-injection (2.4 mg/kg), tracer-infusion was started at
0.04 mg/kg/min, which was continued throughout the measurement. After
2 hr, low-dose insulin was infused at 10 mU/m2/min for 2 hr (Kotronen et al.,
2008), followed by high-dose insulin at 40 mU/m2/min for 2 hr (Brehm et al.,
2006). By variable co-infusion of a 17.5% glucose solution, enriched by
1.1% tracer, plasma glucose concentrations were maintained at 5.0 mmol/l.
For calculation of steady-state kinetics, additional blood samples were taken
in the last 30 min of each step (0, 10, and 40 mU/m2/min insulin).
Postprandial Test
Blood was sampled from a superficial dorsal hand vein, which was arterialized
by placing the hand into a hot-box (50C). Blood samples were taken during
the fasting state (t-30, t-15, t0 min) and postprandial (t = 30, 60, 90, 120, 180,
and 240 min) after ingestion of the test meal. The liquid test meal, that was
consumed within 5 min, provided 2.6 MJ (61 E% fat, 33 E% carbohydrate,
6 E% protein), which was consumed within 5 min at t = 0 (Most et al., 2016).
Indirect Calorimetry
For indirect calorimetry during fasting (30 min) and the 4-hr postprandial state,
the open-circuit ventilated hood system was used (Omnical, Maastricht Uni-
versity) (Schoffelen et al., 1997). Calculations of energy expenditure and sub-
strate oxidation were performed according to the formulas of Weir (1949) and
Frayn (1983). Nitrogen excretion was based on the assumption that protein
oxidation represents 15% of total energy expenditure (Jans et al., 2012).
Gut Permeability Test
After baseline urine collection, subjects drank a 150 ml multisaccharide test
mix [1 g sucrose (Van Gilse, Dinteloord, the Netherlands), 1 g lactulose (Cen-
trafarm, Etten-Leur, the Netherlands), 1 g sucralose (Brenntag, Sittard, the
Netherlands), 1 g erythritol (Danisco Sweeteners, Copenhagen, Denmark),
and 0.5 g of l-rhamnose (Danisco)] (van Wijck et al., 2013). Urine was collected
for determination of the urinary sucrose concentration in the 0–120 min urine
collection, representing gastro-duodenal permeability, whereas in this collec-
tion small intestinal permeability is represented by the lactulose/rhamnose
ratio. Proximal colon permeability is represented by the suclarose/erythritol
ratio of the 120–300 min urine collection.
Biochemical Analyses for Plasma Variables
Blood was collected into pre-chilled tubes and centrifuged at 1,000 3 g, and
plasma was snap-frozen and stored at 80C until analyses. Isotopic enrich-
ment of plasma glucose was determined by electron ionization gas chroma-
tography-mass spectrometry and expressed as tracer-to-tracee ratio for
steady-state calculations of Rd and EGP (Hulzebos et al., 2001). Plasma
glucose, lactate, FFA, and glycerol were determined with the Cobas Fara
auto-analyzer (Roche, Switzerland). Plasma insulin was measured with a dou-
ble antibody radioimmunoassay (Millipore). Plasma leptin concentrations were
analyzed using commercially available radioimmunoassay kits (Human Leptin
RIA, Millipore Corporation). Plasma ANGPTL4 concentrations were measured
by ELISA as described (Kersten et al., 2009). Plasma concentrations of IL-6,
IL-8, and TNF-a were determined using a multiplex enzyme-linked immuno-
sorbent assay (Human ProInflammatory II 4-Plex Ultra-Sensitive Kit, Meso
Scale Diagnositics). Isocratic ion-exchange HPLC (Model PU-1980 pump)
with mass spectrometry (Model LTQ XL, Thermo Fisher Scientific) was usedCell Metabolism 24, 63–74, July 12, 2016 71
to determine sugar concentrations in plasma and urine for gastrointestinal
permeability assessment (van Wijck et al., 2013). LBP was measured using
non-commercial ELISA as described before (Schols et al., 1996). Plasma con-
centrations of GLP-1 were measured by radioimmunoassays as previously
described (Vilsbøll et al., 2003). Plasma BA profile was measured using liquid
chromatography-tandemmass spectrometry (LC-MS/MS) (Vrieze et al., 2014).
The total amount of primary (cholic acid and chenodeoxycholic acid and their
taurine and glycine conjugated forms) and secondary BAs (deoxycholic acid,
lithocholic acid and their conjugated forms) was calculated as the sum of
the individually quantified BA. Plasma SCFAs were determined by LC-MS/
MS as reported before (van Eijk et al., 2009). The detection limits for acetate,
propionate, and butyrate were 0.1, 0.05, and 0.05 mmol/l, respectively.
Laboratory Analysis of Adipose Tissue
Abdominal subcutaneous AT biopsies were taken under local anesthesia
under fasted conditions. One portion was embedded in paraffin. Sections
were cut for staining, digital imaging, and computerized morphometric mea-
surement of individual adipocytes (Goossens et al., 2011). One portion
(500 mg) was snapfrozen in liquid nitrogen, from which RNA was extracted
(Trizol chloroform extraction, Invitrogen) and used for microarray analysis.
100 ng total RNA was labeled by Whole-Transcript Sense Target Assay and
hybridized to human whole-genome Affymetrix Gene 1.1 ST arrays, targeting
19,793 unique genes (Affymetrix). Quality control and data analysis pipeline
have been described in detail previously (Lin et al., 2011). Individual genes
on the array were defined as changed when comparison of the normalized
signal intensities showed a FDRq < 0.05 in a two-tailed paired t test with
Bayesan correction (Limma) (Smyth, 2004). Further functional data analysis
was performed on the filtered dataset with Gene Set Enrichment Analysis
(GSEA, http://www.broad.mit.edu/gsea). Gene sets were selected based
upon FDRq < 0.2.
Laboratory Analysis of Feces
Feces was collected at home for 2 consecutive days at baseline and 7 days
and 8 weeks after intervention using the BMP commode specimen collection
system, and divided over sterile tubes at home. Subjects were provided with a
box of dry ice to freeze their stool samples immediately after defecation at
approximately 80C and for transport to the university. Total fecal amount
was weighed, and 24-hr fecal samples were used to determine energy content
using adiabatic bomb calorimetry (CBB 330, standard benzoic acid 6,320
cal/g, BCS-CRMno90N). 24-hr fecal BA composition was determined by
using gas chromatography (GC) as described before (Hulzebos et al., 2001).
Fecal SCFAs were measured by gas chromatography-mass spectrometry
(GC-MS, Medical laboratory ‘Dr. Stein & Collegae’ Germany), according to
the method described before (Garcı´a-Villalba et al., 2012).
For microbiota profiling, DNA was isolated from 24-hr fecal samples as
described before (Vrieze et al., 2014) and subsequently used for phylogenetic
profiling using the HITchip phylogenetic microarray (Rajilic-Stojanovic et al.,
2009). Standardized quality control was maintained through our library of a
duplicated set of 3,631 probes targeting the 16S rRNA gene sequences of
over 1,000 intestinal bacterial phylotypes. A more detailed description of mi-
crobiota profiling procedures can be found in the Supplemental Experimental
Procedures.
Statistics
The calculated sample size (n = 19 per treatment arm) was based on a 20%
physiologically relevant change of insulin sensitivity (a = 0.05, b = 0.8). All
data were evaluated for normality. Univariate analysis (ANOVA) was applied
to compare group characteristics at baseline. Differences between treatments
were analyzed using repeated-measures ANOVA with time and treatment as
factors. ANCOVA analysis of the delta (post-pre value) was used for parame-
ters when significantly different at baseline, taking the baseline value into ac-
count as covariate. The postprandial response (energy expenditure, substrate
oxidation, and GLP-1) is given as incremental area under the curve (iAUC/min),
which was calculated by the trapezoid method. For HITchip analysis, log10-
transformed signals were used as a proxy for bacterial logarithmic abundance.
To determine which bacterial groups were significantly different in relative
abundance before and after treatment within each group, a paired Wilcoxon
test was used. Between-treatment group effects were assessed with linear72 Cell Metabolism 24, 63–74, July 12, 2016mixed models using the lme4 package (Bates et al., 2015). Benjamini-Hoch-
berg correction was applied for multiple testing. We used Random Forests,
a supervised machine-learning technique, and the pre- and post-treatment
classes to confirm these results (Liaw and Wiener, 2002). To determine
whether individuals could be grouped into classes of specific metabolic re-
sponses to the interventions, we used the lcmm R package (Proust-Lima
et al., 2015) to perform Latent Class Analysis. Diversity of the microbiota
was quantified based on non-logarithmized HITchip oligo-level signals by in-
verse Simpson’s index using the Vegan package (Oksanen et al., 2011).
ANOVA with Tukey’s Honest Significant post hoc analysis was applied to
compare diversity between and within groups. Data are expressed as
means ± SEM, with a two-sided significance level of p < 0.05. Statistical anal-
ysis was performed using SPSS 20.0 for Macintosh and R 3.03.
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